3rd Annual Biosimilars and Biobetters Congress 2015 London

  • Conference Call
  • Oxford Global Conferences Ltd are proud to present the 3rd Annual Biosimilars & Biobetters Congress, taking place on 20 – 21 April 2015 in London, UK at the Novotel London West. The congress is an exclusive opportunity for over 350 biologics experts to exchange their experiences, engage in scientific discussions and debate the best practices and solutions to improve the biosimilars industry performance.

    Despite having to overcome tight regulatory, business and financial challenges, the biosimilars industry is forecast to be worth up to $25 billion by 2020. The rapid growth of the industry requires biosimilar experts to be at the forefront of knowledge with the current landscape of the industry.

    The 3rd Annual Biosimilars & Biobetters Congress forms part of Oxford Global’s highly successful Biologics Series. For more information on other events in this series, please see the details below:

    Agenda

    In keeping with Oxford Global’s highly successful life sciences series, an expert panel of 20 speakers will present a full conference programme covering the topics outlined below. These topics have been compiled as a result of a comprehensive research process undertaken with our advisory board members including VPs, Directors, Senior Research Fellows and Professors from global pharmaceutical organisations and leading research institutions.

    Day 1 – Market Access Strategies, Opportunities And Commercial Challenges

    Day One will explore biosimilars market access strategies, opportunities and commercial challenges. Our esteemed speakers will provide the latest regulatory updates and multiple perspectives on biosimilars. Presentations will also provide an insight into market access initiatives and opportunities in emerging markets, case studies on global commercialisation strategies and evaluating the current market for biosimilars success.

    • Assessing the landscape of biosimilars: interchangeability and substitution
    • Evaluating the current market for biosimilar success: challenges, opportunities and barriers
    • Case studies on global commercialisation strategies
    • Market access initiatives and opportunities in emerging markets
    • Regulatory updates on biosimilars
    • Balancing technological innovation with regulatory requirements

    Day 2 – Developing Biosimilars And Biobetters

    Day Two will focus on biosimilars and biobetters development. Internationally renowned speakers will discuss current challenges and obstacles in the development of biosimilars and the latest solutions to demonstrate biosimilarity. Delegates will also have the opportunity to hear different characterisation methods, industry case studies on biosimilar mAb development and clinical and non-​clinical advances in biosimilars.

    • Demonstrating biosimilarity: challenges and solutions
    • Clinical and non-​clinical advances in biosimilars
    • Characterisation methods: physio-​chemical characterisation, structural characterisation, glycosylation analysis
    • Future challenges and obstacles in biosimilar development
    • Ensuring the quality of follow-​on biologics: analytical testing, downstream processing
    • Analytical development and formulation strategies for follow-​on biologics

    Who is Speaking

    Our speaker programmes are carefully researched each year to ensure that delegates are exposed to the highest level of expertise. However, delegates not only benefit from the experience of our speakers, but also gain an insight into the experiences of other attendees – Q&A sessions and panel discussions are utilised to enable knowledge share and facilitate idea exchange.

    If you have a cutting edge case study or a presentation and would like to join the speaker panel at one of our events, please contact Eszter Nagy.

    2015 Confirmed Speakers

    • Mehrshid Alai-​Safar
      Senior Director Regulatory Affairs, Baxter
    • Ayse Baker
      Director, Lixisenatide Family Projects – Diabetes, Sanofi
    • Chetak Buaria
      Director – Alliance Management (Biosimilars), Merck Serono
    • Matthew Cooper
      Life Sciences Development Director, NHS
    • Richard Dicicco
      Chairman, Harvest Moon Pharmaceuticals USA, Inc.
    • Rakesh Dixit
      Vice President R&D, Global Head, Biologics Safety Assessment, MedImmune
    • Katalin Egyed
      Business Unit Manager Oncology and Oco-​Biotechnology, Egis Pharmaceuticals
    • Uwe Gudat
      Head of Safety, Biosimilars, Merck Serono
    • Ira Jacobs
      Oncology Portfolio Global Medical Lead – Biosimilars, Pfizer
    • Orlando Jaquez
      Technical Development CMC Manager, Biosimilars, Biogen Idec
    • Takashi Kei Kishimoto
      Chief Scientific Officer, Selecta Biosciences
    • Hootan Khatami
      Senior Medical Director, Global Medical Affairs, Sanofi
    • Emmanuelle Lepine
      Vice President of Business Development, Alvotech
    • Patrick Liu
      Senior Director and Global Head of Bioassays, Teva
    • Leandro Mieravilla
      Global Commercial Manager, mABs, Cassara Biotech
    • Malcolm Mitchell
      Senior Medical Fellow, Clinical Pharmacology, Eli Lilly
    • Julie O’Brien
      Senior Manager, Emerging Markets Regulatory Policy, Pfizer
    • Laurent Rebier
      Director, Business Development, Merck Serono
    • Alexandre Richard
      Director – Business Intelligence, Sanofi
    • Joey Studts
      Director Purification and Formulation Science, Boehringer Ingelheim
    • Benita von Glahn
      Head of Regulatory Affairs, Biosimilars, Boehringer Ingelheim

    Submit a poster

    For attendees interested in submitting a poster, there are opportunities now available. Your poster presentation will be located in the exhibition room for two days alongside other posters from senior scientists working in industry and academia.

    How to submit your abstract

    We will require:

    • Poster title, Abstract (200 words or less)
    • Principal author, Organisation, Mailing address
    • Email, Telephone, Fax
    • Additional authors

    In order to secure your board space a fee of £250 plus VAT will be required. The poster should be presented as A0 (841mm x 1189mm) portrait size.

    To take advantage of this opportunity you need to be registered as a paid delegate over the 2 days. We have limited spaces available so please register soon!

    Who Will Attend

    The 3rd Annual Biosimilars & Biobetters Congress is an exclusive event designed for senior level attendees from leading pharmaceutical, biopharmaceutical, biotechnology, diagnostics, CRO and solution provider companies, along with highly esteemed members of academic and government institutions. Delegates typically include VPs, Directors and Global Heads of:

    • Biobetter Development
    • Biologics Development
    • Biosimilar Development
    • Biosimilar Process Development
    • Biosuperiors
    • Commercial Affairs and Development
    • Follow-​On Biologics
    • Market Access
    • Market Entry SBMP
    • Pharmacovigilance
    • Portfolio Management
    • Product Development
    • Regulatory Compliance
    • Regulatory/​Legal Affairs
    • Research & Development
    • Strategic Marketing
    • Strategic Planning
    starting: ending: 21.04.2015 Location: , Category:

    Timeline

    Conference START 21.04.2015 END

    All deadlines have expired!

    This conference has no more open deadlines. There may be successive conferences coming up you may by interested in.

    Please check our conference list and search...

    Conference Facts

    Location , Address Novotel London West, Shortlands 1 Category Organiser More Info Conference Website

    Further interesting Conferences

    Currently we have no similar events listed. Please check our website regulary, subscribe to our RSS-Feed or follow us on twitter for new listings.